Kara M Smith1, Sharon X Xie2, Daniel Weintraub3. 1. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA Parkinson's Disease Research, Education and Clinical Centers (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA Mental Illness Research, Education and Clinical Centers (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Abstract
OBJECTIVE: To describe the incidence of, and clinical and neurobiological risk factors for, new-onset impulse control disorder (ICD) symptoms and related behaviours in early Parkinson disease (PD). METHODS: The Parkinson's Progression Markers Initiative is an international, multicenter, prospective study of de novo patients with PD untreated at baseline and assessed annually, including serial dopamine transporter imaging (DAT-SPECT) and ICD assessment (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease short form, QUIP). Participants were included if they screened negative on the QUIP at baseline. Kaplan-Meier curves and generalised estimating equations examined frequency and predictors of incident ICD symptoms. RESULTS: Participants were seen at baseline (n=320), year 1 (n=284), year 2 (n=217) and year 3 (n=96). Estimated cumulative incident rates of ICD symptoms and related behaviours were 8% (year 1), 18% (year 2) and 25% (year 3) and increased each year in those on dopamine replacement therapy (DRT) and decreased in those not on DRT. In participants on DRT, risk factors for incident ICD symptoms were younger age (OR=0.97, p=0.05), a greater decrease in right caudate (OR=4.03, p=0.01) and mean striatal (OR=6.90, p=0.04) DAT availability over the first year, and lower right putamen (OR=0.06, p=0.01) and mean total striatal (OR=0.25, p=0.04) DAT availability at any post-baseline visit. CONCLUSIONS: The rate of incident ICD symptoms increases with time and initiation of DRT in early PD. In this preliminary study, a greater decrease or lower DAT binding over time increases risk of incident ICD symptoms, conferring additional risk to those taking DRT. CLINICAL TRIAL REGISTRATION: NCT01141023. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: To describe the incidence of, and clinical and neurobiological risk factors for, new-onset impulse control disorder (ICD) symptoms and related behaviours in early Parkinson disease (PD). METHODS: The Parkinson's Progression Markers Initiative is an international, multicenter, prospective study of de novo patients with PD untreated at baseline and assessed annually, including serial dopamine transporter imaging (DAT-SPECT) and ICD assessment (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease short form, QUIP). Participants were included if they screened negative on the QUIP at baseline. Kaplan-Meier curves and generalised estimating equations examined frequency and predictors of incident ICD symptoms. RESULTS:Participants were seen at baseline (n=320), year 1 (n=284), year 2 (n=217) and year 3 (n=96). Estimated cumulative incident rates of ICD symptoms and related behaviours were 8% (year 1), 18% (year 2) and 25% (year 3) and increased each year in those on dopamine replacement therapy (DRT) and decreased in those not on DRT. In participants on DRT, risk factors for incident ICD symptoms were younger age (OR=0.97, p=0.05), a greater decrease in right caudate (OR=4.03, p=0.01) and mean striatal (OR=6.90, p=0.04) DAT availability over the first year, and lower right putamen (OR=0.06, p=0.01) and mean total striatal (OR=0.25, p=0.04) DAT availability at any post-baseline visit. CONCLUSIONS: The rate of incident ICD symptoms increases with time and initiation of DRT in early PD. In this preliminary study, a greater decrease or lower DAT binding over time increases risk of incident ICD symptoms, conferring additional risk to those taking DRT. CLINICAL TRIAL REGISTRATION: NCT01141023. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang Journal: Arch Neurol Date: 2010-05
Authors: Roberto Cilia; Ji Hyun Ko; Sang Soo Cho; Thilo van Eimeren; Giorgio Marotta; Giovanna Pellecchia; Gianni Pezzoli; Angelo Antonini; Antonio P Strafella Journal: Neurobiol Dis Date: 2010-03-22 Impact factor: 5.996
Authors: Daniel Weintraub; Staci Hoops; Judy A Shea; Kelly E Lyons; Rajesh Pahwa; Erika D Driver-Dunckley; Charles H Adler; Marc N Potenza; Janis Miyasaki; Andrew D Siderowf; John E Duda; Howard I Hurtig; Amy Colcher; Stacy S Horn; Matthew B Stern; Valerie Voon Journal: Mov Disord Date: 2009-07-30 Impact factor: 10.338
Authors: T D L Steeves; J Miyasaki; M Zurowski; A E Lang; G Pellecchia; T Van Eimeren; P Rusjan; S Houle; A P Strafella Journal: Brain Date: 2009-04-03 Impact factor: 13.501
Authors: Amy L Phu; Zheyu Xu; Vlasios Brakoulias; Neil Mahant; Victor S C Fung; Gregory De Moore; Andrew Martin; Vladan Starcevic; Martin Krause Journal: J Clin Neurosci Date: 2013-09-10 Impact factor: 1.961
Authors: I Navalpotro-Gomez; R Dacosta-Aguayo; F Molinet-Dronda; A Martin-Bastida; A Botas-Peñin; H Jimenez-Urbieta; M Delgado-Alvarado; B Gago; A Quiroga-Varela; Maria C Rodriguez-Oroz Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-04 Impact factor: 9.236
Authors: Ingrid de Chazeron; Franck Durif; Isabelle Chereau-Boudet; Maria Livia Fantini; Ana Marques; Philippe Derost; Berengere Debilly; Georges Brousse; Yves Boirie; Pierre Michel Llorca Journal: Eat Weight Disord Date: 2019-02-04 Impact factor: 4.652